Sol­id Bio­sciences ap­pears to be prep­ping for an IPO with $50M round for Duchenne gene ther­a­py

Sol­id Bio­sciences has come up with a $50 mil­lion crossover round that would ap­pear to be po­si­tion­ing the com­pa­ny for an IPO as it ad­vances a gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy in­to the clin­ic.

Found­ed by Duchenne dad — and for­mer JP Mor­gan in­vest­ment banker — Ilan Gan­ot, the Cam­bridge, MA-based biotech at­tract­ed RA Cap­i­tal and Bain to the lead roles in the new round. RA is a well known crossover in­vestor while Bain has be­gun to spread its wings with a new fund.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.